Navigation Links
VirtualScopics' Scientists to Present at International Society for Magnetic Resonance in Medicine 17th Scientific Meeting and Exhibition
Date:4/16/2009

ROCHESTER, N.Y., April 16 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that Drs. Edward Ashton and Jonathan Riek will be among the invited presenters at the International Society for Magnetic Resonance in Medicine (ISMRM) 17th Scientific Meeting and Exhibition scheduled in Honolulu, Hawaii from April 18 - April 24, 2009.

Dr. Ashton, chief scientific officer at VirtualScopics, will present a paper entitled "Early DCE-MRI Findings Predict Tumor Volume Changes" on Tuesday, April 21, 2009 at 5:10 PM (HST). Dr. Ashton will also present a second paper, "Quantitative MR in Multi-Center Clinical Trials" as part of the Imaging Biomarker Educational Course on Thursday, April 23, 2009 at 1:30 PM (HST).

Dr. Riek, VirtualScopics' vice president of technology and product development, will present "Use of a Dual-Echo Fast-Spin-Echo Sequence for T2 Mapping of Cartilage within a Clinical Trial" during the poster session at 2:30 PM (HST) on Thursday, April 23, 2009.

"Dr. Riek and I are proud to have been selected to speak at the upcoming ISMRM meeting," stated Dr. Ashton. He added, "VirtualScopics is working at the forefront of MR imaging's applications in clinical trials and has witnessed first-hand the benefits of quantitative MR imaging in the drug development arena. Therefore, we greatly appreciate ISMRM's continued support and determination in furthering the research, development, and education in the field of MR imaging."

Upon the close of the meeting, the three presentations will be available for viewing in the Publications section of the company's website, www.virtualscopics.com.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the project balance (backlog) and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation and the risk that they may not get signed. Other risks include the company's dependence on its largest customers, the amount of new contract awards coming from its largest customer, and risks associated with contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

    CONTACT:        Company Contact:
                    Molly Henderson
                    Chief Business and Financial Officer
                    500 Linden Oaks
                    Rochester, New York 14625
                    (585)249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Announces $4.35 Million Private Placement
2. VirtualScopics Backlog Exceeds a Record $20 Million
3. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
4. VirtualScopics Reports Second Quarter 2008 Results
5. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
6. VirtualScopics to Present at Two Upcoming Investor Conferences
7. VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
8. VirtualScopics Backlog Rises to a Record $27 Million
9. VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference
10. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
11. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology: